NS 863
Alternative Names: NS-863Latest Information Update: 04 Jan 2024
At a glance
- Originator Nippon Shinyaku
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cardiovascular disorders
Most Recent Events
- 08 Aug 2023 Phase-I clinical trials in Cardiovascular disorders (In volunteers) in Japan (PO) (JRCT2071230038)